| Identification | Back Directory | [Name]
ML355 | [CAS]
1532593-30-8 | [Synonyms]
ML355
ML 355;ML-355;ML355
N-(benzo[d]thiazol-2-yl)-4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide
N-2-Benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]benzenesulfonamide
Benzenesulfonamide, N-2-benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]- | [Molecular Formula]
C21H19N3O4S2 | [MDL Number]
MFCD28167822 | [MOL File]
1532593-30-8.mol | [Molecular Weight]
441.52 |
| Chemical Properties | Back Directory | [Melting point ]
>182°C (dec.) | [Boiling point ]
654.5±65.0 °C(Predicted) | [density ]
1.481±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Pyridine (Very Slightly) | [form ]
Solid | [pka]
7.58±0.30(Predicted) | [color ]
Pale Beige to Beige |
| Hazard Information | Back Directory | [Uses]
ML355 is used in the synthesis, structural activity relationship of benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase. | [in vivo]
ML355 (1.88-30 mg/kg; i.g.; 2 times per day for two days) strongly inhibits the thrombus formation in mice at higher dose compared to WT controls[3]. | Animal Model: | C57BL/6 mice[3] | | Dosage: | 1.88, 3.75, 7.5, 15, 30 mg/kg | | Administration: | Oral gavage; 2 times per day for two days | | Result: | The thrombus formation in mice was strongly inhibited by higher doses of ML355. |
| [IC 50]
12-LOX: 0.34 μM (IC50) |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|